
Opinion|Videos|January 16, 2025
Navigating Between Front-line Systemic Therapies in uHCC.
Author(s)James J. Harding, MD
James J. Harding, MD, compares the responses observed with nivolumab plus ipilimumab (NIVO + IPI) therapy in the CheckMate 9DW trial to other first-line (1L) immunotherapy (IO) regimens for unresectable hepatocellular carcinoma (uHCC), including the HIMALAYA 5-year update (STRIDE) and the IMbrave150 trial (atezolizumab [ATEZO] + bevacizumab [BEV]), highlighting differences in efficacy and treatment outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Consider the other 1L systemic therapies in uHCC. How do the responses with NIVO + IPI therapy in CheckMate 9DW compare with other 1L IO regimens? HIMALAYA 5-year update (STRIDE),
Rimassa et al, ESMO 2024 and IMbrave150 (ATEZO + BEV),Cheng et al, J Hepatol 2022 .
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















